The Next Big Catalysts for DRTS that will take it to The Next Level

DRTS just secured a commercial approval in Japan, that means the former clinical stage company is turning into the commercial platform and industry leader it can be. But that’s only the beginning of what 2026 holds for DRTS, with major catalysts lined up all throughout the year and beyond. The FDA Phase 3 Trial is completing this quarter, yes that’s Q1 2026 (and we’re already in March). The results will be announced this year and they already started submitting the data for approval. The Pancreatic Cancer trial is also wrapping up, will be done in H1 2026 and results will be announced this year (this indication alone is worth billions in market cap, that’s many multiples from where the stock is now). The GBM trial results will be shared this year as well, and even just prolonging the life expectancy or improving life quality is worth billions, while we already know the two patients treated so far are doing great. The most secret catalyst is the combination therapy trial with Keytruda, the last update was a long time ago and a new one is due. Keytruda is the #1 selling drug in the world, and the trial results were DRTS boosting the numbers from 19% response rate for Keytruda alone to effectively 100%(!) response rate when adding the DRTS treatment. They are also launching new FDA trials, completing the manufacturing facility in the US and working towards the one in Japan, treating Lung Cancer patients and Breast Cancer patients and many more patients in many more cancers even the most high unmet needs and hard (considered impossible) to treat. The CEO was recently interviewed and said he is not looking to raise capital because he has all these catalysts coming, only after will he consider it (with the stock price much higher than it is today), but mentioned he’s already having many strategic discussions with other companies wanting to get involved. NFA but Do Yourself A Favor and DYOR, there’s a lot to be excited about as everything is coming together and lining up perfectly for a generational run.